Table 3.
Hazard ratios for studied end points according to treatment at baseline
| Glucose-lowering drug | Cardiovascular mortality | Composite of cardiovascular mortality and non-fatal MI |
All-cause mortality | |||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| Metformin | 1 | 1 | 1 | |||
| Insulin | 1.47 | 1.29-1.68 | 1.46 | 1.29-1.66 | 1.47 | 1.30-1.66 |
| Glibenclamide | 1.31 | 1.13-1.51 | 1.34 | 1.17-1-54 | 1.26 | 1.10-1.44 |
| Glimepiride | 1.15 | 1.00-1.33 | 1.15 | 1.01-1.32 | 1.14 | 1.00-1.31 |
| Glipizide | 1.19 | 1.01-1.40 | 1.24 | 1.06-1.44 | 1.18 | 1.01-1.37 |
| Gliclazide | 1.04 | 0.83-1.30 | 1.09 | 0.89-1.35 | 1.00 | 0.81-1.23 |
| Tolbutamide | 1.19 | 1.01-1.40 | 1.22 | 1.05-1.43 | 1.16 | 0.99-1.35 |
| All sulfonylureas | 1.20 | 1.05-1.37 | 1.22 | 1.08-1.38 | 1.17 | 1.04-1.32 |
Hazard ratios (HRs) and 95% confidence intervals (CIs) for adverse cardiovascular end points according to glucose-lowering drug (monotherapy) at baseline. Time-dependent Cox analyses were performed with adjustments for age, sex, socioeconomic status, calendar year, concomitant pharmacotherapy, and comorbidity. MI = Myocardial infarction.